Healthcare
TuHURA Biosciences, Inc.(HURA)
Live Price
Offline$2.57
+15.77% today
1Y Change
+18.39%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $140.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +48.1%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TuHURA Biosciences, Inc. (HURA) is a Healthcare stock with a market cap of $140.00M and listed on NASDAQ. The stock last traded around $2.57 and up 18.4% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +48.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +48.1%, free cash flow -87.4% with operating margin 0.0% and ROIC -147.0%. Stock Foundry combines HURA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 15, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +48.1%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 15, 2026 | โ | +10.4% | +8.2% | -1.7% |
2026 Mar 31, 2026 | -5.4% | -9.5% | +1.1% | +17.3% |
2025 Nov 14, 2025 | +6.7% | -8.3% | -15.1% | -53.0% |
Benchmark Edge
HURA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HURA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HURA Max Drawdown
-86.46%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HURA and SPY.
Company Overview
TuHURA Biosciences, Inc.
NASDAQ Capital Market
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
- Leadership
- James A. Bianco
- IPO Date
- Feb 22, 2013
- Employees
- 19
- Street Address
- 10500 University Center Drive
- Mailing
- Tampa
- Region
- Tampa, US
- Reporting Currency
- USD
- Investor Line
- +1 813 514 8373
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 5.1
Growth
- Revenue
- 0.0%
- EPS
- +48.1%
- Free Cash Flow
- -87.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -179.4%
- ROIC
- -147.0%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 0.78
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.